Targeting the disordered C terminus of PTP1B with an allosteric inhibitor.

Abstract : PTP1B, a validated therapeutic target for diabetes and obesity, has a critical positive role in HER2 signaling in breast tumorigenesis. Efforts to develop therapeutic inhibitors of PTP1B have been frustrated by the chemical properties of the active site. We define a new mechanism of allosteric inhibition that targets the C-terminal, noncatalytic segment of PTP1B. We present what is to our knowledge the first ensemble structure of PTP1B containing this intrinsically disordered segment, within which we identified a binding site for the small-molecule inhibitor MSI-1436. We demonstrate binding to a second site close to the catalytic domain, with cooperative effects between the two sites locking PTP1B in an inactive state. MSI-1436 antagonized HER2 signaling, inhibited tumorigenesis in xenografts and abrogated metastasis in the NDL2 mouse model of breast cancer, validating inhibition of PTP1B as a therapeutic strategy in breast cancer. This new approach to inhibition of PTP1B emphasizes the potential of disordered segments of proteins as specific binding sites for therapeutic small molecules.
Type de document :
Article dans une revue
Nature Chemical Biology, Nature Publishing Group, 2014, 10 (7), pp.558-66
Liste complète des métadonnées

http://hal.univ-grenoble-alpes.fr/hal-01131138
Contributeur : Frank Thomas <>
Soumis le : vendredi 13 mars 2015 - 08:44:01
Dernière modification le : jeudi 11 janvier 2018 - 06:24:34

Identifiants

Collections

Citation

Navasona Krishnan, Dorothy Koveal, Daniel H Miller, Bin Xue, Sai Dipikaa Akshinthala, et al.. Targeting the disordered C terminus of PTP1B with an allosteric inhibitor.. Nature Chemical Biology, Nature Publishing Group, 2014, 10 (7), pp.558-66. 〈hal-01131138〉

Partager

Métriques

Consultations de la notice

115